Combination therapy shown as effective for higher-risk MDS/AML patients

(University of Texas M. D. Anderson Cancer Center) A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news